• Explore /
  • Poster
  • / Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).

Abstract Poster

Authors

null

Clinton Yam

The University of Texas MD Anderson Cancer Center, Houston, TX

Clinton Yam , Elizabeth A. Mittendorf , Ryan Sun , Lei Huo , Senthil Damodaran , Gaiane M Rauch , Rosalind P Candelaria , Beatriz E Adrada , Sahil Seth , William Fraser Symmans , Rashmi Krishna Murthy , Jason B White , Elizabeth Ravenberg , Alyson Clayborn , Sabitha Prabhakaran , Vicente Valero , Alastair Mark Thompson , Debu Tripathy , Stacy L. Moulder , Jennifer Keating Litton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02530489

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 592)

DOI

10.1200/JCO.2021.39.15_suppl.592

Abstract #

592

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Lajos Pusztai

First Author: Jessica N. Snider

First Author: Zefei Jiang

First Author: Kay T Yeung